MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/eurheartj/ehad771

Медицинская библиотека · European heart journal · 2024

Anticoagulation with edoxaban in patients with long atrial high-rate episodes ≥24 h.

Becher Nina, Toennis Tobias, Bertaglia Emanuele, Blomström-Lundqvist Carina, Brandes Axel, Cabanelas Nuno, Calvert Melanie, Camm A John, Chlouverakis Gregory, Dan Gheorghe-Andrei, Dichtl Wolfgang, Diener Hans Christoph, Fierenz Alexander, Goette Andreas, de Groot Joris R, Hermans Astrid N L, Lip Gregory Y H, Lubinski Andrzej, Marijon Eloi, Merkely Béla, Mont Lluís, Ozga Ann-Kathrin, Rajappan Kim, Sarkozy Andrea, Scherr Daniel, Schnabel Renate B, Schotten Ulrich, Sehner Susanne, Simantirakis Emmanuel, Vardas Panos, Velchev Vasil, Wichterle Dan, Zapf Antonia, Kirchhof Paulus

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND AND AIMS: Patients with long atrial high-rate episodes (AHREs) ≥24 h and stroke risk factors are often treated with anticoagulation for stroke prevention. Anticoagulation has never been compared with no anticoagulation in these patients.

METHODS

This secondary pre-specified analysis of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High-rate episodes (NOAH-AFNET 6) trial examined interactions between AHRE duration at baseline and anticoagulation with edoxaban compared with placebo in patients with AHRE and stroke risk factors. The primary efficacy outcome was a composite of stroke, systemic embolism, or cardiovascular death. The safety outcome was a composite of major bleeding and death. Key secondary outcomes were components of these outcomes and electrocardiogram (ECG)-diagnosed atrial fibrillation.

RESULTS

Median follow-up of 2389 patients with core lab-verified AHRE was 1.8 years. AHRE ≥24 h were present at baseline in 259/2389 patients (11%, 78 ± 7 years old, 28% women, CHA2DS2-VASc 4). Clinical characteristics were not different from patients with shorter AHRE. The primary outcome occurred in 9/132 patients with AHRE ≥24 h (4.3%/patient-year, 2 strokes) treated with anticoagulation and in 14/127 patients treated with placebo (6.9%/patient-year, 2 strokes). Atrial high-rate episode duration did not interact with the efficacy (P-interaction = .65) or safety (P-interaction = .98) of anticoagulation. Analyses including AHRE as a continuous parameter confirmed this. Patients with AHRE ≥24 h developed more ECG-diagnosed atrial fibrillation (17.0%/patient-year) than patients with shorter AHRE (8.2%/patient-year; P < .001).

CONCLUSIONS

This hypothesis-generating analysis does not find an interaction between AHRE duration and anticoagulation therapy in patients with device-detected AHRE and stroke risk factors. Further research is needed to identify patients with long AHRE at high stroke risk.

Для цитирования: Becher Nina, Toennis Tobias, Bertaglia Emanuele, Blomström-Lundqvist Carina, Brandes Axel, Cabanelas Nuno, Calvert Melanie, Camm A John, Chlouverakis Gregory, Dan Gheorghe-Andrei, Dichtl Wolfgang, Diener Hans Christoph, Fierenz Alexander, Goette Andreas, de Groot Joris R, Hermans Astrid N L, Lip Gregory Y H, Lubinski Andrzej, Marijon Eloi, Merkely Béla, Mont Lluís, Ozga Ann-Kathrin, Rajappan Kim, Sarkozy Andrea, Scherr Daniel, Schnabel Renate B, Schotten Ulrich, Sehner Susanne, Simantirakis Emmanuel, Vardas Panos, Velchev Vasil, Wichterle Dan, Zapf Antonia, Kirchhof Paulus. Anticoagulation with edoxaban in patients with long atrial high-rate episodes ≥24 h.. European heart journal. 2024. DOI: 10.1093/eurheartj/ehad771.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.